Medical Condition News

RSS

Turning microRNAs into novel drugs

Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.

20 Mar 2010

Winner of 2010 European Magnetic Resonance Award

Dr John Griffiths, a Cancer Research UK-funded scientist, has received the 2010 European Magnetic Resonance Award for Basic Sciences.

20 Mar 2010

High dose of Zocor could lead to muscle injury, warns FDA

The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg.

20 Mar 2010

China Sky One Medical's Myocardial Infarction and Urine Microalbumin Diagnostic Kits receive CE certification

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the receipt of Conformite Europeenne (CE) certification for its Myocardial Infarction and Urine Microalbumin Diagnostic Kits. The CE marking certifies that the two products have met the European Union health and safety standards and are approved for sale in the 27 EU countries and four members of the European Free Trade Association.

20 Mar 2010

Innovative tissue damage preventing cardiac scaffold awarded Rappaport Prize for biomedical research

Prof. Smadar Cohen, head of the University's Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, has been awarded the prestigious Rappaport Prize for Excellence in Biomedical Research, an award totaling $100,000. The prize, given by Israel's Rappaport Foundation, is presented annually to a researcher whose research has either significantly advanced or has the potential to significantly advance any medical or biomedical field.

20 Mar 2010

SoCalBio to host forum on latest medical devices for treating obesity

The Southern California Biomedical Council will host a discussion on the latest medical devices for treating obesity during its networking forum on Thursday, March 25th (7:00 - 9:30 am) at the UC Irvine University Club.

20 Mar 2010

Melancholy - not just a ‘state of mind’ but maybe a mental illness

Melancholia was first identified by the Greek physician Hippocrates, who described sufferers as being plagued with ''fears and despondencies''. But due to lack of exact biochemical and clinical features this condition has been struck off the Diagnostic and Statistical Manual of Mental Disorders used worldwide to diagnose mental illnesses.

19 Mar 2010

Cedars-Sinai Neurovascular Center's clinical trial of minimally invasive stenting procedure for TIA

Individuals between 30 and 80 years of age, who have had a transient ischemic attack (TIA) or non-severe stroke within the past 30 days, and who cannot be treated surgically, may be eligible to participate in a Phase III clinical trial of a minimally invasive stenting procedure at the Cedars-Sinai Neurovascular Center. The study will focus specifically on patients who have had an intracranial artery narrowed by at least 70 percent and who are experiencing recurrent strokes or TIAs despite being on anti-clotting medication.

19 Mar 2010

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma Incorporated today announced the presentation of two abstracts relating to Cinryze™ (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.

19 Mar 2010

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

ViroPharma Incorporated today announced the launch of 'Ryze Above' (www.ryzeabove.com), an exclusive patient resources program within the company's patient support program, CINRYZESolutions®. The Ryze Above program was created for HAE patients prescribed Cinryze, the first and only drug specifically approved to help prevent swelling and/or painful attacks in teenagers and adults with HAE.

19 Mar 2010

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the initiation of dosing in a Phase IIa clinical trial of SP-304 in patients with chronic constipation (CC). This is a Phase IIa, randomized, double-blind, placebo-controlled, 14-day repeat, oral, dose-escalation study in patients with chronic constipation.

19 Mar 2010

Trauma patients with undiagnosed Helicobacter infections: Some drugs may not be effective

A Kansas State University study aimed at alleviating intestinal damage in trauma patients digressed to an important finding that could affect medication given to the individuals.

19 Mar 2010

Community-driven approaches needed for reducing cancer-death disparities

Cancer death rates for African-Americans far exceed non-Hispanic Caucasians in the United States, and only community-driven approaches to reducing health disparities will lessen the gap, says Edward Partridge, M.D., president-elect of the American Cancer Society (ACS) National Board of Directors and director of the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center.

19 Mar 2010

White paper describes health and economic burden of diabetes on Americans

PositiveID Corporation announced today that it has published a white paper entitled “Fixing the Black Hole in Diabetes Management,” which describes the health and economic burden of diabetes on Americans and our economy.

19 Mar 2010

BioTrends publishes new LaunchTrends report on Actemra

BioTrends is pleased to announce the publication of a new syndicated report, LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first IL-6 receptor inhibitor agent approved for rheumatoid arthritis. This report is the first in a three wave series and is derived from on-line survey responses from 77 rheumatologists and qualitative interviews with 20 rheumatologists.

19 Mar 2010

Lifestyle improvements and new treatments for diabetes and cardiovascular disease needed

Treatment with the anti-hypertensive drug valsartan (Diovan) led to a modest reduction in the development of type 2 diabetes but did not significantly reduce cardiovascular events in patients with impaired glucose tolerance, according to researchers at Duke University Medical Center and the University of Oxford. They jointly reported results at the American College of Cardiology meeting today from the world's first study designed to find ways to control the progression to diabetes and cardiovascular disease in people at risk.

19 Mar 2010

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

Roche today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy. The CHMP positive opinion clears the way for European Union approval and means that this group of patients may soon be able to benefit from earlier treatment with Tarceva.

19 Mar 2010

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease following four cycles of standard platinum-based first-line chemotherapy.

19 Mar 2010

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting.

19 Mar 2010

Study reveals higher-than-normal blood levels of fructose in pancreatic cancer patients

Patients with pancreatic cancer have higher-than-normal blood levels of the refined sugar fructose, according to a recent study in the journal Pancreas, official journal of the American Pancreatic Association and the Japan Pancreas Society. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

19 Mar 2010

Medical Condition News

Turning microRNAs into novel drugs

Winner of 2010 European Magnetic Resonance Award

High dose of Zocor could lead to muscle injury, warns FDA

China Sky One Medical's Myocardial Infarction and Urine Microalbumin Diagnostic Kits receive CE certification

Innovative tissue damage preventing cardiac scaffold awarded Rappaport Prize for biomedical research

SoCalBio to host forum on latest medical devices for treating obesity

Melancholy - not just a ‘state of mind’ but maybe a mental illness

Cedars-Sinai Neurovascular Center's clinical trial of minimally invasive stenting procedure for TIA

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients

Trauma patients with undiagnosed Helicobacter infections: Some drugs may not be effective

Community-driven approaches needed for reducing cancer-death disparities

White paper describes health and economic burden of diabetes on Americans

BioTrends publishes new LaunchTrends report on Actemra

Lifestyle improvements and new treatments for diabetes and cardiovascular disease needed

European CHMP issues positive opinion for Roche's Tarceva as maintenance therapy for NSCLC

CHMP issues positive opinion recommending approval of Tarceva as monotherapy for NSCLC

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

Study reveals higher-than-normal blood levels of fructose in pancreatic cancer patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News